Purpose: Claudin-8 (CLDN8) has been identified as an androgen-regulated gene in prostate cancer. However, the role of CLDN8 has not been fully explored in breast cancer. We aimed to explore the expression of CLDN8 and androgen receptor (AR), determine the correlation between CLDN8 and AR, assess the prognostic value of CLDN8 and AR co-expression, and investigate the possible CLDN8 expression molecular mechanism in breast cancer.
Materials and Methods: Twenty-eight pairs of fresh tumor tissues and adjacent noncancerous tissues were evaluated by Western blot for CLDN8. Then, 142 breast cancer samples were determined by immunohistochemistry for CLDN8 and AR. The association of clinicopathological features with CLDN8, AR and CLDN8, and AR co-expression was examined. The Cancer Genome Atlas (TCGA) was used to demonstrate the expression of CLDN8 and correlation between CLDN8 and AR. Kaplan–Meier survival analysis was performed to assess the prognostic impact of CLDN8 and AR co-expression. The mechanisms related to CLDN8 expression in breast cancer were explored by Gene Set Enrichment Analysis (GSEA).
Results: CLDN8 was downregulated in breast cancer tissues and positively correlated with none lymph node metastasis (P =0.016), low histological grade (P =0.006), positive ER (P =0.014), positive PR (P =0.003), low Ki-67 index (P =0.017) and molecular subtypes (P =0.012). CLDN8 level was significantly associated with AR level (r=0.348; P < 0.001). CLDN8 and AR co-expression was positively correlated with none lymph node metastasis (P =0.007), low histological grade (P =0.017), positive ER (P =0.019), positive PR (P =0.015) and low Ki-67 index group (P =0.038). CLDN8 and AR co-expression had a better clinical prognosis.
Conclusion: The expression of CLDN8 is directly related to the expression of AR. CLDN8 and AR co-expression might be a potential prognostic evaluation factor for breast cancer patients.
Keywords: claudin-8, androgen receptor, breast cancer, prognosis